.jpeg)
Can Panitumumab be reimbursed by medical insurance?
The original drug Panitumumab (Panitumumab) has not yet been launched in the country, and no domestically produced panitumumab has been launched in the country, so it has not entered the ranks of medical insurance. Panitumumab, a monoclonal antibody used to treat metastatic colorectal cancer (mCRC), is an epidermal growth factor receptor (EGFR) antagonist that works by preventing the growth of cancer cells. It is given as an intravenous (IV) injection every 14 days, usually along with chemotherapy. If Panitumumab’s original drug and domestically produced drug can be approved by the State Food and Drug Administration and pass the relevant policies of the National Medical Insurance Bureau, you can apply for medical insurance for reimbursement. For specific drug information, consult the local Medical Insurance Bureau and other places.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
